Can we prevent, reduce or reverse intestinal fibrosis in IBD?

Area of Science:

• Gastroenterology
• Immunology
• Pathology

Background:

• Intestinal fibrosis is a prevalent complication in inflammatory bowel disease (IBD), particularly Crohn's disease (CD).
• It results from chronic inflammation and abnormal extracellular matrix deposition by myofibroblasts.
• Existing anti-inflammatory treatments for IBD do not prevent or reverse established fibrosis and strictures.

Purpose of the Study:

• To explore the mechanisms underlying intestinal fibrosis in IBD.
• To identify potential targets for novel anti-fibrotic therapies.
• To address clinical needs in monitoring fibrotic progression and treatment efficacy.

Main Methods:

• Review of current literature on intestinal fibrosis pathogenesis in IBD.
• Analysis of cellular and molecular mechanisms involved in fibrosis development.
• Discussion of clinical challenges and future research directions.

Main Results:

• Current IBD therapies do not halt or reverse intestinal fibrosis.
• The incidence of intestinal strictures in CD remains unchanged despite therapeutic advances.
• Control of inflammation does not necessarily impact the fibrotic process.

Conclusions:

• The understanding of intestinal fibrosis is evolving, challenging the view of it being irreversible.
• Further research into fibrosis mechanisms could yield new anti-fibrotic agents for IBD.
• Identifying fibrosis drivers and effective monitoring methods are crucial for future IBD management.